以上内容基于公开资料整理，不构成投资建议。 昊海生科 昊海生物科技 分时图 日K线 周K线 月K线 46.13 -0.34 -0.73% 0.77% 0.52% 0.26% 0.00% 0.26% 0.52% 0.77% 46.11 46.23 46.35 46.47 46.59 46.71 46.83 09:30 10:30 11:30/13:00 14:00 15:00 15:30 0 8152 2万 2万 经济观察网2026年2月12日，昊海生科发布公告称，股东楼国梁因自身资金需要，计划通过集中竞价和 大宗交易方式减持不超过100万股公司股份，占公司总股本的比例不超过0.4337%。截至公告日，楼国 梁持有公司股份约712万股，持股比例为3.0882%。该减持计划自公告披露后3个交易日起的3个月内实 施，可能对短期市场情绪构成压力。 股票近期走势 受股东减持公告影响，昊海生科股价近期表现偏弱。截至2026年2月13日开盘，股价报46.47元，近5日 累计下跌1.09%。2月12日单日下跌0.81%，成交额约1978.85万元，主力资金净流出6.53万元，显示短期 资金面承压。同期，医药生物板块整体微跌0 ...

Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating potential investor concerns and market volatility [1] - On February 12, Junshi Biosciences' stock fell by 1.23%, with a trading volume of 243 million yuan, and a net financing outflow of approximately 14.89 million yuan [1] - As of February 12, the total margin balance for Junshi Biosciences was 1.423 billion yuan, with a financing balance of 1.412 billion yuan, representing 5.33% of the circulating market value, which is above the 90th percentile of the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% increase [2] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]

Company Overview - The company, established in 2016, focuses on the ophthalmology sector and aims to become a global leader in innovative ophthalmic therapies [5] - It has developed a competitive and differentiated product pipeline addressing various ophthalmic indications with significant unmet clinical needs [5] Core Products - VVN461 (high dose) is a novel dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), currently undergoing Phase III clinical trials in China for non-infectious anterior uveitis (NIAU) [5][6][8] - VVN001 is a second-generation LFA-1 antagonist designed for treating dry eye disease (DED), with ongoing Phase III clinical trials in China [10][11] Clinical Trials and Approvals - VVN461 received IND approval from the National Medical Products Administration (NMPA) in January 2023 and has shown comparable anti-inflammatory efficacy to corticosteroids in clinical trials [8][7] - VVN001 has also received IND approval and has demonstrated higher efficacy and safety compared to the standard treatment, cyclosporine A [11][10] Financial Information - The company reported other income and gains of RMB 8.572 million and RMB 3.444 million for the nine months ending September 30 in 2024 and 2025, respectively [12][14] - Research and development expenses were approximately RMB 128.261 million and RMB 65.178 million for the same periods, with annual losses of RMB 201.535 million and RMB 131.495 million [13][14] Industry Overview - The global ophthalmic drug market is estimated to reach USD 41.6 billion in 2024, with a projected CAGR of 2.8% from 2024 to 2029, driven by an aging population and increasing prevalence of eye diseases [15][18] - The Chinese ophthalmic drug market is expected to grow from USD 2.7 billion in 2020 to USD 4.1 billion in 2024, with a CAGR of 10.8%, and further growth anticipated to USD 6.6 billion by 2029 [18]

机构观点 营收增长主要依赖核心产品艾可宁及新业务，但增速已降至个位数。净利润亏损同比增亏，主要因2024 年处置子公司收益缺失；研发费用投入1.38亿元至1.45亿元，同比微增，聚焦小核酸药物管线。公司坦 言新药研发周期长、风险高。 股票近期走势 近期股价波动明显，近5日下跌0.82%，反映市场对公司业绩及研发风险的谨慎情绪。 经济观察网前沿生物发布2025年业绩预告，预计营收1.4亿元至1.45亿元，同比增长8.13%至11.99%，增 速持续下滑；归属净利润亏损扩大至2.55亿元至2.9亿元。公司研发重心转向小核酸药物，多款产品处于 早期阶段。 财报分析 分析指出，公司核心产品放量受行业免费药物格局制约，小核酸药物虽为长期增长点，但均处临床前或 早期阶段，未来面临审批、竞争等多重风险。公司需突破盈利瓶颈。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - Tyligand Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, planning to list on the Hong Kong Stock Exchange under the 18A rule with a primary focus on small molecule drugs and ADC candidates [1][3]. Financial Performance - The company reported revenues of approximately RMB 0.08 billion for 2024 and RMB 0.11 billion for the first nine months of 2025, reflecting a year-on-year increase of 654.18% [4]. - The net losses were RMB 0.70 billion in 2024 and RMB 1.23 billion in the first nine months of 2025, with a year-on-year increase of 335.23% [4]. - Gross margins were reported at 90.64% for 2024 and 78.31% for the first nine months of 2025 [4]. - Research and development expenses were RMB -0.73 billion for 2024 and RMB -0.91 billion for the first nine months of 2025, with a year-on-year increase of 80.62% [4]. Drug Development Pipeline - The company has a drug portfolio that includes four candidates, with TSN1611 being the core product currently in Phase 2 clinical trials in the US and China for non-small cell lung cancer (NSCLC) [1][3]. - TSN1611 is a highly selective oral KRAS G12D inhibitor, with plans for a pivotal registration trial in China [1]. Industry Overview - The global market for KRAS G12D inhibitors is projected to grow from USD 81.8 million in 2027 to USD 3,481.6 million by 2035, with a compound annual growth rate (CAGR) of 59.8% [8]. - The Chinese market for KRAS G12D inhibitors is expected to increase from USD 12.3 million in 2027 to USD 446.5 million by 2035, with a CAGR of 56.7% [8][9]. Competitor Analysis - Comparable companies in the industry include Jinfang Pharmaceutical-B, Hengrui Medicine, and Revolution Medicines, with varying IPO details and financial metrics [12]. - Tyligand Biosciences has a current gross margin of 90.64%, which is competitive within the industry [12]. Management and Shareholding Structure - The board of directors consists of five members, including two executive directors and three non-executive directors [13]. - Major shareholders include Tyligand Holdings, which holds 23.66% of the company, with significant stakes from other investors such as Tencent and Kangzhe Pharmaceutical [15]. Financing History - The company has undergone multiple rounds of financing, with the latest B round valuing the company at approximately USD 222.2 million [17].

【瑞博生物】电话会小结 – 与Madrigal达成BD，6千万美元首付款+43亿美元里程碑【东吴医药朱国广团队】 与MDGL的互补合作：MASH适应症大市场，双方互赢，①肝病非常适合小核酸去做，MDGL对未来临床需要达到 的效果有很好的刻画，瑞博具备临床前到临床的转化经验和数据，因此可以倒算出临床前的数据要求，完全符合 要求，因此达成了合作。 ②MDRL已经是MASH领域先行者，MDRL拥有Rezdi ④对瑞博来说，MASH临床前数据优秀，但是并不是公司临床聚焦的方向，临床也很难做，最优解就是合作授 权。 ⑤达成合作的6个管线，并不相同，具有互补机制。 #未来2年内至少达到一个mash的IND，或有数kw美元的收入。 与BI的合作：BI与MDGl的靶点、适应症领域均有区别，BI更注重晚期肝病和并发症，聚焦FIC的科学突破性创新 靶点。 目前进展符合预期，已经拿到2个里程碑，预计与MDGL的合作管线同期会进入IND。 创新技术：肾靶向领先全球 + 其他的肝外递送早期资产 + 双靶点。 与MDGL的互补合作：MASH适应症大市场，双方互赢，①肝病非常适合小核酸去做，MDGL对未来临床需要达到 的效果有很好的刻画， ...

Company and Industry Summary Company: WuXi Biologics Key Points - **High Growth in Dual Antibody and ADC**: WuXi Biologics is experiencing rapid growth in dual antibodies (双多抗) and antibody-drug conjugates (ADC), with a significant market share that positions the company to potentially outperform in new molecular tracks [1][1] - **Revenue Contribution**: Dual antibodies currently contribute nearly 20% of the group's revenue, with a year-on-year growth exceeding 120% [1][1] - **Project Pipeline**: In 2025, two-thirds of the new projects signed by the company will be in dual antibodies and ADC, with approximately half of these projects originating from the United States [1][1] - **ADC Projects**: The company has a total of 252 ADC projects, indicating a sustained upward trend in market conditions for this segment [1][1] - **Market Share in Dual Antibodies**: WuXi Biologics holds a market share of over 55% in the dual antibody domain, with expectations for the M-end to release growth potential as project conversion progresses [1][1] - **Record Project Numbers**: The company is set to achieve a record number of projects in 2025, with a significant increase in PPQ (Process Performance Qualification) projects [1][1] - **Total Projects**: By the end of 2025, the total number of projects is expected to reach 945, including 74 in Phase 3 clinical trials and 25 commercial projects [1][1] - **PPQ Projects Timeline**: The company plans to complete 28 PPQ projects in 2025 and has scheduled 34 PPQ projects for 2026, indicating a continuous increase in project activity [2][2] - **Commercialization Timeline**: It is estimated that it takes about two years from PPQ to commercial production, with the M-end's commercialization potential expected to accelerate post-2027 [2][2] - **Revenue and Profit Forecast**: Projected revenues for 2025, 2026, and 2027 are estimated at 21.79 billion, 25.92 billion, and 31.02 billion yuan respectively, with adjusted net profits of 5.71 billion, 6.94 billion, and 8.49 billion yuan [2][2] - **Valuation Metrics**: Corresponding valuations based on current market capitalization are projected to be 28x, 23x, and 19x for the years 2025, 2026, and 2027 respectively [2][2] Risk Factors - **Geopolitical Risks**: The company faces potential geopolitical risks that could impact operations and market performance [3][3] - **Sales Performance Risks**: There is a risk that the sales of commercialized products may not meet expectations [3][3]

Core Insights - Rongchang Biotech is expected to achieve multiple clinical advancements, product approvals, and partnership milestones by 2026 [1] Stock Performance - The overseas Phase III clinical trial for Taitasip in treating myasthenia gravis continues to enroll participants, with completion anticipated in the first half of 2026 [2] - Taitasip has received FDA fast track designation for primary Sjögren's syndrome, with a global Phase III trial likely to commence [2] - The global Phase II registration trial for Vidisizumab in second-line urothelial carcinoma has been completed, and the accelerated enrollment for the Phase III trial in first-line urothelial carcinoma is ongoing, with Pfizer expected to submit an overseas marketing application in the first half of 2026 [2] Project Progress - New indications for Vidisizumab and the ophthalmic drug RC28 are expected to receive approval in the second to third quarter of 2026 [3] - The indication for Taitasip in IgA nephropathy is anticipated to be approved in the fourth quarter [3] - Core product RC148 (PD-1/VEGF dual antibody) has three Phase III clinical trials approved, with overseas development plans being noteworthy [3] Related Transactions - An upfront payment of $650 million from the licensing agreement with AbbVie for RC148 will be reflected in the 2026 performance, with the total transaction amount reaching $5.6 billion [4] - Subsequent milestone payments from collaborations with Vor Bio and Santen Pharmaceutical may also progress [4] Product Development Progress - RC278 (targeting CDCP1 ADC) has entered Phase I/II clinical trials [5] - RC288 (bispecific ADC) is planned to initiate clinical trials in early 2026 [5]

Company Overview - Yimufeng Biotech is a leading global innovative cell therapy company, with its core product IMC002 being a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate, currently in pivotal Phase III clinical trials for solid tumors [2] - The company also has a first-in-class anti-EpCAM CAR-T cell therapy candidate (IMC001) in Phase I/IIa clinical trials, targeting various epithelial-derived tumors, and a proprietary manufacturing process for cost-effective CAR-T production [3] - Yimufeng Biotech aims to leverage the large patient population for solid tumors in China and globally, creating significant market potential [2] Financial Information - For the fiscal year 2024, the company reported other income and revenue of approximately 3.36 million RMB, 2.137 million RMB for the nine months ended September 30, 2024, and 2.877 million RMB for the nine months ended September 30, 2025 [4] - Research and development expenses for the fiscal year 2024 were recorded at 54.44 million RMB, 38.574 million RMB for the nine months ended September 30, 2024, and 48.694 million RMB for the nine months ended September 30, 2025 [5] Industry Overview - CAR-T therapy is expanding significantly from hematologic malignancies to solid tumors and autoimmune diseases, presenting substantial growth opportunities [8] - The treatment shows promising efficacy against blood cancers, and researchers are developing innovative strategies to address challenges in solid tumor treatment [8] - The CAR-T field is evolving through traditional technology improvements and the development of new platforms, with next-generation CAR designs enhancing targeting precision and safety [8]

智通财经APP获悉，据港交所2月13日披露，深圳易慕峰生物科技股份有限公司(简称：易慕峰生物)向港 交所主板递交上市申请，华泰国际为其独家保荐人。 | : [编纂]股H股(視乎[编纂] | 编纂]的[編纂]數目 | 行使與否而定) | | | | | --- | --- | --- | --- | --- | --- | | [編纂]數目 | . | [编纂]股H股(可予[編纂]) | [編纂]數目 | .. | [編纂]股H股(可予[編纂]及視乎 | | [編纂]行使與否而定) | : | 最高[編纂] | 每股H股[編纂]港元,另加1.0%經紀 | | | | 佣金、0.0027%證監會交易徵費、 | 0.00015%會財局交易徵費及 | | | | | | 0.00565%聯交所交易費(須於[編纂] | 時以港元繳足,多繳款項可予退還) | | | | | | .. | 面值 | 每股H股[編纂] | : [0] | [編纂] | | | your sites (ra shop 1 - 1 = 1 | | | | | | 公司简介 据招股书，易慕峰生物是一家全球领先的创新型细胞治疗公司。公司的核心产品 ...